NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

zero82,

Thanks for your insights about “big pharma” 😶

Both DCVax®-L & the polarized aDC1 platform are included in active PII combo trials with
Merck’s pembrolizmab & participants in those trials are being treated TODAY.

The forthcoming COMBO trial for ovarian cancer involves the polarized aDC1 platform too…

The NIH database entry for Dr. Kalinski’s previous grant award may provide insight into the potential design of the ovarian cancer combo trial:

🇺🇸U.S. National Institutes of Health Grants Database



Perhaps even more valuable than the funding itself, the validation that comes with a rigorously peer-reviewed grant award is immensely significant!



Dr. Kalinski




University of Pittsburgh Hillman Cancer Center



The polarized aDC1 platform has also been studied in breast cancer with promising results…

The Dava Oncology Breast Cancer Summit was a noteworthy event last August—deserved more attention. NWBO’s polarized aDC1 platform technology was featured, & combo with checkpoint blockade was highlighted!

Dr. Shipra Gandhi was the principal on the aDC1 combo trial NCT04348747 before joining the Winship Cancer Institute at Emory University. Dr. Sheheryar Kabraji is the current principal of the study, & he also attended the conference.

Starting Now: Cellular Therapies and Vaccine Strategies
Moderated by: Dr. Vinay Jain #DAVABreast pic.twitter.com/fl2E6KiHtB

— DAVA Oncology (@DAVAOnc) August 23, 2025

Starting Now: Novel Immune Checkpoint Approaches
Moderated by: @Dr_RShatsky @UCSDHealth #DAVABreast pic.twitter.com/MAopMWbirC

— DAVA Oncology (@DAVAOnc) August 23, 2025

Can we re-engage anti-HER2/3 immunity in brain-metastatic breast cancer? Dr. @gandhi_shipra from @WinshipAtEmory presents a dendritic cell vaccine + PD-1 combo approach in CNS disease (NCT04348747), with a novel Th1/CTL-driven strategy at #DAVABreast #BreastCancer pic.twitter.com/OTgEhph8CR

— DAVA Oncology (@DAVAOnc) August 21, 2025

Thanks @DAVAOnc for a great week full of new learning and connections and renewing old friendships https://t.co/4hxE4obErG

— Sheheryar Kabraji (@SKabrajiMD) August 25, 2025

ASCO 2025 Abstract